Moderna and Merck’s AI-Designed Cancer Vaccine Clears Phase 3, a First for Personalized mRNA Therapy
Moderna and Merck announced on August 19, 2026 that their AI-designed, patient-specific mRNA melanoma vaccine met its main goals in a Phase 3 trial, the first randomized late-stage success for an individualized cancer vaccine.